Drug Profile
Research programme: cancer therapeutic - LIDDS/Ferring Pharmaceuticals
Alternative Names: NZ FERRINGLatest Information Update: 01 Aug 2022
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals; LIDDS
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Jul 2022 LIDDS has patent protection for NanoZolid® production process in Israel
- 28 Aug 2021 No recent reports of development identified for research development in Cancer in Sweden (Injection, Controlled release)
- 28 Aug 2021 No recent reports of development identified for research development in Cancer in Switzerland (Injection, Controlled release)